AKT1 and hepatocellular carcinoma: For instance, doxorubicin is the most common treatment in hepatocellular carcinoma (HCC), and acquired chemoresistance to doxorubicin in HCC is associated with activation of the PI3-K/Akt and mitogen-activated protein kinase (MAPK) signaling pathways.